Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.9600
+0.0723 (8.14%)
At close: Mar 17, 2026, 4:00 PM EDT
0.8800
-0.0800 (-8.33%)
After-hours: Mar 17, 2026, 7:59 PM EDT
Longeveron Revenue
In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%. Longeveron had revenue of $365.00K in the quarter ending December 31, 2025, a decrease of -39.47%.
Revenue (ttm)
$1.20M
Revenue Growth
-49.87%
P/S Ratio
15.54
Revenue / Employee
$57,480
Employees
25
Market Cap
22.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Marker Therapeutics | 4.69M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
| Daré Bioscience | -57.13K |
LGVN News
- 8 hours ago - Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 hours ago - Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - GlobeNewsWire
- 12 hours ago - Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
- 6 days ago - Longeveron Announces Closing of Private Placement of up to $30 Million - GlobeNewsWire
- 7 days ago - Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
- 20 days ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 4 weeks ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 5 weeks ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire